Thermo Fisher ScientificTMO
TMO
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Employees: 125,000
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
42% more call options, than puts
Call options by funds: $1.45B | Put options by funds: $1.02B
0.24% more ownership
Funds ownership: 87.81% [Q1] → 88.05% (+0.24%) [Q2]
5% less funds holding
Funds holding: 2,533 [Q1] → 2,397 (-136) [Q2]
15% less repeat investments, than reductions
Existing positions increased: 880 | Existing positions reduced: 1,031
19% less capital invested
Capital invested by funds: $165B [Q1] → $134B (-$30.7B) [Q2]
29% less first-time investments, than exits
New positions opened: 179 | Existing positions closed: 253
49% less funds holding in top 10
Funds holding in top 10: 83 [Q1] → 42 (-41) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$480
2%
downside
Avg. target
$532
8%
upside
High target
$590
20%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
UBS Dan Leonard | 2%upside $500 | Neutral Maintained | 24 Jul 2025 |
Raymond James Andrew Cooper | 9%upside $535 | Outperform Reiterated | 24 Jul 2025 |
Wells Fargo Brandon Couillard | 15%upside $565 | Overweight Maintained | 24 Jul 2025 |
Barclays Luke Sergott | 0%downside $490 | Equal-Weight Maintained | 24 Jul 2025 |
Baird Catherine Schulte | 16%upside $567 | Outperform Maintained | 24 Jul 2025 |
Financial journalist opinion
Based on 16 articles about TMO published over the past 30 days
Positive
Zacks Investment Research
3 days ago
Thermo Fisher (TMO) Up 1.8% Since Last Earnings Report: Can It Continue?
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?
Neutral
Business Wire
4 days ago
Thermo Fisher Scientific Opens Manufacturing Center of Excellence Site in North Carolina
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its innovative manufacturing center of excellence facility in Mebane, N.C. The new 375,000-square-foot carbon neutral site will be capable of producing at least 40 million laboratory pipette tips per week, helping to ensure that life-saving medicines and therapies continue to be developed and produced in the U.S. for decades to come. “As a global leader in li.
Positive
The Motley Fool
6 days ago
Why Thermo Fisher Scientific Stock Was Topping the Market Today
An analyst launched coverage of Thermo Fisher Scientific (TMO 2.15%) after market close on Monday, and the stock was experiencing a little pop the following day as a result. On Tuesday, it closed more than 2% higher in price, contrasting well with the 0.6% slide of the benchmark S&P 500 (^GSPC -0.59%).
Positive
Benzinga
6 days ago
Thermo Fisher Positioned As Biopharma's Partner Of Choice
Could Thermo Fisher Scientific Inc. TMO be the unsung hero of the biopharma sector's future? While its stock performance has recently lagged, analysts are betting on a major turnaround driven by strategic acquisitions and robust growth potential.
Positive
Zacks Investment Research
1 week ago
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.
Neutral
CNBC Television
1 week ago
Final Trades: Toast, Transdigm, Thermo Fisher and Amazon
The Investment Committee give you their top stocks to watch for the second half.
Positive
Seeking Alpha
2 weeks ago
Thermo Fisher: Growth Acceleration And Margin Expansion Should Drive The Upside
Revenue growth is accelerating, led by pharma/biotech momentum and bioproduction demand. The medium-term margin outlook is positive with cost cuts, AI-driven efficiencies, and lapping of tariff headwinds starting next year. Valuation attractive vs. history and peers, supporting potential re-rating.
Neutral
Business Wire
2 weeks ago
Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment
CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS® (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim. The test allows clinicians and pathologists to assess if non-small cell lung cancer (NSCLC) tumors harbor human epi.
Positive
Seeking Alpha
2 weeks ago
Thermo Fisher: The Rerating Is Just Getting Started - Buy
Thermo Fisher is emerging from a challenging period with solid fundamentals, strong cash flow, and renewed growth, making it undervalued by the market. Recent earnings showed organic growth, margin expansion, and raised guidance, signaling a return to normalcy and operational strength. Valuation models indicate 15–48% upside, driven by recurring revenues, loyal customers, and potential for multiple expansion as confidence returns.
Positive
Seeking Alpha
2 weeks ago
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robust pipeline, and potential to triple revenues by 2030.
Charts implemented using Lightweight Charts™